Dr. Adam Giermasz, MD, PhD

Dr. Giermasz practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Giermasz's NPI, 1831374644, was assigned on December 31, 2007. Dr. Giermasz graduated from Medical University of Warsaw in 1998. Dr. Giermasz holds California license A103790.

Dr. Giermasz's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Giermasz's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Giermasz to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Giermasz practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Giermasz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Giermasz is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Giermasz's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists chronic anemia, chronic leukemia, deep vein thrombosis (DVT), lung cancer, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Giermasz treats.

CMS data shows 327 Medicare services from Dr. Giermasz across 8 procedure codes in 2024, for 208 Medicare patients. Medicare paid $28,139 for them.

CMS counts 208 Medicare patients who saw Dr. Giermasz in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Giermasz's median patient age at 55, with 51% women.

In 2024, Dr. Giermasz wrote 230 Medicare Part D claims for 56 patients. 11% of them were for generic drugs. CMS names the drug for 209 of them, across 3 drugs with 11 or more claims each, at $233,493 in total drug cost. In 2023, CMS named 212 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Giermasz for performance year 2024, reported as part of a group. Dr. Giermasz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Giermasz as offering telehealth.

Dmand AI links 22 papers to Dr. Giermasz, published from 2002 to 2025. 2024 was the busiest year, with 2. The most frequent topics are Hemorrhage, Dependovirus and Genetic Therapy. Dr. Giermasz has published most often in Blood Adv. Dr. Giermasz's most frequent co-authors are Nigel S. Key, MD, Steven W. Pipe, MD and Andrew D. Leavitt, MD.

Dmand AI links Dr. Giermasz to 3 clinical trials, 3 of them phase 4 studies. 1 is still active or recruiting. Conditions studied include Hemophilia A, Antiphospholipid Syndrome and Hemophilia B.

CMS Open Payments shows 539 general payments to Dr. Giermasz from 17 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 43% of the total. Sanofi and Genzyme US Companies paid the most, $123,260. It also lists 31 research payments totaling $26,130 from 2020 to 2025.

Dmand AI lists 1 award for Dr. Giermasz, most recently CMS Stage 1 EHR in 2013.

Dr. Giermasz graduated from Medical University of Warsaw in 1998.

Dr. Giermasz is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.